Tolbutamide treatment in diabetic dogs significantly increased left ventricular end-diastolic pressure compared to untreated diabetics (12.1 vs 6.1 mm Hg; P<0.01) and altered myocardial morphology.
Absolute Event Rate: 12.1% vs 6.1%
p-value: p=<0.01
The effects of chronic tolbutamide treatment were examined in a diabetic animal model in which abnormal myocardial function and composition have previously been demonstrated. Eight diabetic dogs were given tolbutamide 250 mg/day orally and compared with seven untreated diabetics, five healthy dogs receiving tolbutamide, and eight normal controls. After one year, resting hemodynamic studies in the intact anesthetized state showed that treated diabetic dogs had a significantly higher left ventricular end-diastolic pressure of 12.1+/-1.3 mm Hg associated with normal end-diastolic volume, compared to 6.1+/-0.8 mm Hg in untreated diabetics (P less than 0.01) and 6.3+/-0.5 in normals. Stroke work and ejection fraction were similar to normals. Acute volume expansion revealed a larger rise of left ventricular end-diastolic pressure in treated and untreated diabetics than normals, without a significant stroke volume response in treated diabetics. Enhanced stiffness of myocardium appeared to be related to interstitial accumulation of periodic acid-Schiff staining material, further intensified in treated diabetics by triglyceride accumulation observed on electron microscopy and by chemical analysis. Thus treatment of diabetes with tolbutamide, despite improved glucose tolerance, effected further reduction of left ventricular function and altered morphology of myocardium.
Wu et al. (1977) studied Experimental diabetes (n=28). Tolbutamide vs. Untreated diabetics and normal controls was evaluated on Left ventricular end-diastolic pressure (mm Hg) (p=<0.01). Tolbutamide treatment in diabetic dogs significantly increased left ventricular end-diastolic pressure compared to untreated diabetics (12.1 vs 6.1 mm Hg; P<0.01) and altered myocardial morphology.